ATH-1020 / Athira Pharma - LARVOL DELTA

Ath-1020, a novel small-molecule positive modulator of neurotrophic HGF system, is neuroprotective and improves motor function in preclinical models of Parkinson’s disease (Neuroscience 2024) - "These cellular changes translated into enhanced motor function in a rat model of PD. These findings highlight the potential of ATH-1020 for the treatment of neurodegenerative diseases including PD."

Preclinical • CNS Disorders • Parkinson's Disease • HGF • IL1B • IL6 • TNFA

Safety, Tolerability, and Pharmacokinetics Study of ATH-1020 (clinicaltrials.gov) - P1 | N=32 | Completed | Sponsor: Athira Pharma | Recruiting ➔ Completed | N=68 ➔ 32

Enrollment change • Trial completion

Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting (GlobeNewswire) - "Athira Pharma, Inc...today announced a planned poster presentation at the upcoming American Academy of Neurology (AAN) 2024 Annual Meeting, to be held April 13 – 18, 2024, in Denver, Colorado and online. The presentation will highlight preclinical data supporting the continued development of Athira's pipeline of small molecule candidates targeting the neurotrophic hepatocyte growth factor (HGF) system, including fosgonimeton for Alzheimer’s disease, ATH-1105 for amyotrophic lateral sclerosis (ALS), and ATH-1020 for Parkinson’s disease."

Preclinical • Alzheimer's Disease • Amyotrophic Lateral Sclerosis • CNS Disorders • Parkinson's Disease

Targeting Neurotrophic HGF Signaling for the Treatment of Neurodegenerative Disorders (AAN 2024) - "We have developed first generation (fosgonimeton) and second generation (ATH-1020 and ATH-1105) small molecules designed to promote neurotrophic HGF system activity, with distinct properties to allow for potential therapeutic application in various neurodegenerative disorders.Design/To evaluate neurotrophic effects, primary neurons were treated with fosgonimeton, ATH-1020, or ATH-1105 and neurite outgrowth and synaptic count were measured. These results demonstrate the neurotrophic, neuroprotective, and anti-inflammatory effects of positive modulators of the HGF system. Consistent treatment effects across diverse models of neurodegenerative disorders supports the broad therapeutic potential of targeting neurotrophic HGF signaling."

Alzheimer's Disease • Amyotrophic Lateral Sclerosis • CNS Disorders • Inflammation • Movement Disorders • Parkinson's Disease • TARDBP

Athira Pharma to Present Data Supporting Therapeutic Potential of Enhancing HGF/MET Neurotrophic System at Upcoming Scientific Conferences (GlobeNewswire) - "Athira Pharma, Inc...today announced that it will participate in two upcoming scientific conferences: American Society for Experimental Neurotherapeutics (ASENT) 2023 Annual Meeting, which will be held virtually from Mar. 13-15, 2023, and AD/PD™ 2023 International Conference on Alzheimer's and Parkinson's Diseases (AD/PD), which will be held in Gothenburg, Sweden and virtually from Mar. 28-Apr. 1, 2023."

Preclinical • Alzheimer's Disease • Amyotrophic Lateral Sclerosis • CNS Disorders • Parkinson's Disease • Peripheral Neuropathic Pain

Safety, Tolerability, and Pharmacokinetics Study of ATH-1020 (clinicaltrials.gov) - P1 | N=68 | Recruiting | Sponsor: Athira Pharma | Not yet recruiting ➔ Recruiting

Enrollment open

Athira Pharma Presents Preclinical Data of Fosgonimeton (ATH-1017) and ATH-1020 at the American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting (GlobeNewswire) - “Data presented for ATH-1020, Athira’s first oral candidate, demonstrate in vitro and in vivo efficacy, including its ability to augment MET activation, promote activation of downstream signaling pathways and, in two distinct animal models, mitigate depression-like behaviors and normalize an EEG hallmark of schizophrenia. These findings support the potential of ATH-1020 as an oral treatment for neuropsychiatric conditions and its advancement into clinical development....Athira is conducting a Phase 1 trial of ATH-1020 in healthy volunteers (NCT05169671) to evaluate safety, tolerability, and pharmacokinetics. The company expects to dose the first volunteer in the study in the first quarter of 2022.”

Preclinical • Trial status • CNS Disorders • Schizophrenia